BackTempest Therapeutics Overview

Tempest Therapeutics Total Current Liabilities

Track Tempest Therapeutics's total current liabilities ($3.3M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$3.31M
74.87% YoYΔ $-9.87M vs prior year quarter

Peer average

Loading

Tempest Therapeutics Total Current Liabilities History

Loading

Tempest Therapeutics vs. peers: Total Current Liabilities Comparison

Loading

Tempest Therapeutics Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Tempest Therapeutics (TPST) FAQ

Tempest Therapeutics's total current liabilities stands at $3.3M as of March 2026. That compares with $13M in the prior-year period — down 74.9% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Tempest Therapeutics reported $3.3M in total current liabilities versus $13M a year earlier — a 74.9% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $13M in the prior-year period — down 74.9% year over year. Sustained growth in total current liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Tempest Therapeutics's total current liabilities evolved across reporting periods, while the comparison chart places TPST next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, total current liabilities is commonly used to spot outliers. Tempest Therapeutics's reading of $3.3M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.